knowledge -WSS

knowledge

author：knowledge 2025-08-03 03:30:50 - browse：34

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： 340B reform proposal comes out of Senate working group

entertainment

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

Flu vaccine offering decent levels of protection this winter, new data show

Padmanee Sharma of MD Anderson at center of lawsuit over credit

House looks to weaken Medicare negotiation

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FDA does about

focus

knowledge

explore

Walensky prepares to leave CDC — and Congress — behind

Obesity now affects over 1 billion people worldwide, study finds

Cancer drug shortages should be causing more outrage

340B reform proposal comes out of Senate working group

23andMe had bad news about my health. I wish a person had delivered it

Medicare Advantage plans can’t deny care with AI, CMS warns

Medicare details structure of new drug price negotiation program

340B reform proposal comes out of Senate working group

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Scientists unlock the key to scar

focus

Problems with a popular proposal to regulate AI in health care

Devoted Health’s losses in Medicare Advantage persist

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

An inside look at PIPEs, biotech's buzzy new financing tool

Unique patient identifier: Experts argue the benefits, pitfalls

ALS groups 'won't be played again' by the FDA, drug sponsors

Wikipedia

entertainment

leisure time

hotspot